Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Insiders Sell Benda Shares despite Positive India News

publication date: Nov 15, 2007

After the closing bell yesterday, Benda Pharmaceutical reported the company’s gene therapy for cancer, Gendicine®, was doing well in clinical trials in India. Benda said Gendicine® had “passed major milestones,” and Benda expects the drug to eventually be approved for sale in India during 2008. Nevertheless, Benda sold off 30% in today’s trading, hitting a new 52-week low. ChinaBio(tm) Today found out that the selling came from an unrelated source: the shares from a one-year-old, $12 million PIPE transaction were free to trade today and some investors were cashing out.  More details...

Stock Symbol: (OTCBB: BPMA)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital